OC
IMRX icon

Oppenheimer & Co’s Immuneering IMRX Stock Holding History

Oppenheimer & Co’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$179K Buy
+34,000
New +$174K ﹤0.01% 1593

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oppenheimer & Co's IMRX Position: Q1 2026 in Review

Oppenheimer & Co opened a new position in Immuneering (IMRX) in Q1 2026: 34,000 shares worth $179K. The stake represents ﹤0.01% of the portfolio and ranks #1593 among its holdings.

95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Oppenheimer & Co held 34,000 shares of Immuneering worth $179K as of Q1 2026.
  • Immuneering was a new Oppenheimer & Co position in Q1 2026.
  • Immuneering made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1593 holding.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.